Bruker Corporation (NASDAQ:BRKR) Receives $50.62 Average Price Target from Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have been given an average recommendation of “Hold” by the seventeen ratings firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $51.3846.

A number of research firms have issued reports on BRKR. Redburn Partners set a $60.00 target price on shares of Bruker in a research note on Thursday, November 20th. The Goldman Sachs Group started coverage on shares of Bruker in a research note on Tuesday, December 9th. They issued a “sell” rating and a $40.00 price objective for the company. Cowen reissued a “hold” rating on shares of Bruker in a research report on Tuesday, November 4th. Rothschild Redb raised Bruker to a “strong-buy” rating in a research report on Thursday, November 20th. Finally, Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective on the stock in a report on Wednesday, December 10th.

Insider Buying and Selling at Bruker

In related news, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the completion of the sale, the director directly owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This represents a 15.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

A number of hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its stake in shares of Bruker by 377.5% in the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after purchasing an additional 487 shares during the period. Allworth Financial LP increased its position in Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the period. Huntington National Bank lifted its holdings in shares of Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after buying an additional 645 shares during the last quarter. Spire Wealth Management acquired a new stake in shares of Bruker in the second quarter worth $32,000. Finally, Caitong International Asset Management Co. Ltd increased its position in Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after acquiring an additional 745 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Bruker Trading Up 4.1%

NASDAQ BRKR opened at $46.48 on Friday. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81. Bruker has a 1-year low of $28.53 and a 1-year high of $64.64. The firm’s fifty day simple moving average is $42.66 and its 200-day simple moving average is $38.60. The company has a market capitalization of $7.06 billion, a PE ratio of -290.50, a price-to-earnings-growth ratio of 6.57 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The firm had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The business’s quarterly revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, sell-side analysts anticipate that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 8th will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s dividend payout ratio (DPR) is currently -125.00%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.